Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor.

Abstract

We successfully treated 3 consecutive patients who had nonneutropenic rhinocerebral zygomycosis, by use of subcutaneous granulocyte-macrophage colony-stimulating factor therapy combined with traditional surgical and medical treatment. All patients are currently free of disease. Granulocyte-macrophage colony-stimulating factor should be considered as adjuvant therapy for rhinocerebral zygomycosis; however, optimum dose and length of therapy are unknown.

• Authors: J B Garcia-Diaz, L Palau, G A Pankey
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 32 Issue 12 Pg. e145-50 (Jun 15 2001) ISSN: 1058-4838 [Print] United States
• PMID: 11360225 (Publication Type: Case Reports, Journal Article)

Chemical References

• Adjuvants, Pharmaceutic
• Drug Combinations
• Phosphatidylcholines
• Phosphatidylglycerols
• liposomal amphotericin B
• Amphotericin B
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Adjuvants, Pharmaceutic (administration & dosage, therapeutic use)
• Aged
• Amphotericin B (therapeutic use)
• Drug Combinations
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage, therapeutic use)
• Humans
• Male
• Middle Aged
• Mucormycosis (drug therapy, pathology, surgery)
• Phosphatidylcholines (therapeutic use)
• Phosphatidylglycerols (therapeutic use)
• Rhizopus (drug effects, isolation & purification)
• Treatment Outcome